Society for Medical Decision Making. Boston MA (USA), 1990/10/22.
The advent of effective prophylactic treatments for asymptomatic persons infected with human immunodeficiency virus has led to interest in widespread screening programs.
However, the costs of screening programs and therapy are high, and the prevalence of infection above which screening becomes an appropriate use of scarce health care dollars remains undetermined. methods: To examine the cost-effectiveness of screening in populations with differing prevalences of infection, we developed a Markov model to compare costs and life expectancy for two strategies: (1) screening and prophylactic treatment for infected persons who have or who develop low CD4+(T4) cell counts, and (2) no screening.
Mots-clés Pascal : Immunopathologie, Immunodéficit acquis syndrome, Virose, Infection, Economie santé, Dépistage, Homme, Analyse coût efficacité
Mots-clés Pascal anglais : Immunopathology, AIDS, Viral disease, Infection, Health economy, Medical screening, Human, Cost efficiency analysis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0476019
Code Inist : 002B06D01. Création : 199406.